Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MMP14 | P50281 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23902077 | 1.00 | MMP1 (0.33) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL23902100 | 1.00 | MMP1 (0.33) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL13996012 | 0.95 | SHBG (0.36) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL13995986 | 0.93 | SHBG (0.39) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL13995983 | 0.93 | SHBG (0.39) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL23902139 | 0.93 | TDP1 (0.33) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL23902074 | 0.84 | MMP1 (0.39) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL23902079 | 0.84 | MMP1 (0.39) | MMP1MMP9MMP14MMP2MMP3 | |
| SCHEMBL23902072 | 0.82 | ALDH1A1 (0.34) | — | |
| SCHEMBL23902110 | 0.82 | ALDH1A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | MMP1 3804/4885MMP9 3490/4885MMP14 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.